GlassScriptPhysician profile
Albertus B Van Zyl
NPI 1063409423
$972.33
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $824 · 2020: $148.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $152.83 | 2019 | |
| Pfizer INC. | $148.78 | 2019-2020 | |
| Novo Nordisk INC | $137.36 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $117.87 | 2019 | |
| Janssen Pharmaceuticals, INC | $80.10 | 2019-2020 | |
| Amgen INC. | $77.66 | 2019 | |
| Glaxosmithkline, LLC. | $40.03 | 2019 | |
| Astellas Pharma US INC | $36.00 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.72 | 2019 | |
| Sanofi Pasteur INC. | $32.82 | 2019 | |
| Abbott Laboratories | $23.28 | 2020 | |
| Arbor Pharmaceuticals, INC. | $17.58 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.74 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.98 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.94 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $13.95 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.69 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albertus Van Zyl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.